Avexitide Clinical Trials

Size	Price	Qty
1mg	USD 209
5mg	USD 597

Clinical Trials

Avexitide has been evaluated in several clinical trials targeting metabolic conditions characterized by excessive insulin secretion and postprandial glucose dysregulation. Research focuses on indications including post-bariatric hypoglycemia and acquired hyperinsulinemic hypoglycemia across Phase 2 and Phase 3 clinical evaluations. Clinical study sponsors range from corporate entities such as Amylyx Pharmaceuticals Inc. to academic lead investigators, including Dr. Tracey McLaughlin. Completed Phase 2 trials have assessed drug efficacy, tolerability, and pharmacokinetic profiles (NCT04652479, NCT02771574), while advanced clinical development includes an active, non-recruiting Phase 3 trial evaluating therapeutic efficacy in post-bariatric hypoglycemia (NCT06747468).

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06747468	ACTIVE_NOT_RECRUITING	Post Bariatric Hypoglycemia	Amylyx Pharmaceuticals Inc.	2025-04-29	PHASE3
NCT04652479	COMPLETED	Acquired Hyperinsulinemic Hypoglycemia	Dr. Tracey McLaughlin, MD	2021-06-21	PHASE2
NCT02771574	COMPLETED	Post Bariatric Hypoglycemia	Tracey McLaughlin	2016-05	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-24)

Check the Avexitide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Avexitide functions as a specific, competitive antagonist of the glucagon-like peptide-1 (GLP-1) receptor, selectively binding the receptor and blocking downstream GLP-1-mediated intracellular signaling cascades that promote insulin release. By inhibiting excessive GLP-1 receptor activation on pancreatic beta cells and preventing exaggerated insulin secretion, this targeted antagonism helps stabilize blood glucose dynamics in conditions such as post-bariatric hypoglycemia and acquired hyperinsulinemic hypoglycemia.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).